摘要
分离麻醉剂艾司氯胺酮是一种新型抗抑郁药,通过非竞争性拮抗N-甲基-D-天冬氨酸受体,激活α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体,增加脑源性神经营养性因子及单胺类神经递质释放,促进突触再生等多重机制发挥抗抑郁作用。难治性双相和单相抑郁症患者应用艾司氯胺酮治疗均可快速缓解抑郁症状,有自杀倾向的抑郁症患者可迅速消除自杀意图,且艾司氯胺酮的安全性优于消旋体氯胺酮,患者耐受性较好。本文就艾司氯胺酮的药物动力学、抗抑郁作用机制的研究进展作一综述。
Esketamine,an isolated anesthetic,is proven to be a new type of antidepressant,which can play an antidepressive role through multiple mechanisms,such as non-competitively antagonizing N-methyl-D-aspartate receptor,activatingα-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor,increasing the release of brain-derived neurotrophic factor,and improving neuroplasticity and synapse regeneration.In recent years,the clinical studies have shown that esketamine can provide rapid relief to both bipolar depression and unipolar depression,and can quickly eliminate the suicidal intention of patients with suicidal depression.Compared with racemic ketamine,it has greater safety and tolerability.This paper reviews the research progress of the pharmacodynamics and mechanism of esketamine on depression.
作者
李普乐
康霞
吕爽
张加强
LI Pu-le;KANG Xia;LYU Shuang;ZHANG Jia-qiang(Department of Anesthesia and Perioperative Medicine,Zhengzhou Utiiversity People's Hospital,Henan Provincial People's Hospital,Zhengzhou,Henan 450003,China)
出处
《中华实用诊断与治疗杂志》
2021年第7期750-752,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
河南省医学科技攻关计划省部共建项目(SB201901090)。
